{
  "id": 15893115,
  "title": "AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?",
  "url": "https://urgent.news/2026/10/21/abbvie-vs-bristol-myers-squibb-faster-growth-or-steady-revenue",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-21T13:00:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/charts/2026/10/21/abbvie-vs-bristol-myers-squibb-faster-growth-or-steady-revenue/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "AbbVie and Bristol Myers Squibb are two pharmaceutical companies with distinct strategies in generating revenue and growth. AbbVie primarily focuses on developing advanced therapies in immunology, oncology, and neuroscience. The company recently acquired Apogee Therapeutics, expanding its pipeline in dermatology and respiratory treatments. AbbVie has secured regulatory approvals for multiple therapies in international markets. Its revenue is expected to grow significantly, from $67.2 billion to $67.2 billion, while its net income is forecasted to increase from $4.2 billion to $14.6 billion.\n\nOn the other hand, Bristol Myers Squibb (BMY) primarily earns revenue from treatments for cancer, cardiovascular disease, and immunological conditions. The company has secured accelerated regulatory approval for a combination therapy for multiple myeloma in the United States and is working on constructing a new manufacturing campus. Bristol Myers Squibb aims to bring 10 new drugs to market by the end of the decade, an ambitious goal given that 2027 is just a few months away. The company's stock is currently considered cheap, but this may indicate that investors have not yet fully recognized its potential.\n\nWhile both companies have their strengths, AbbVie appears to be the better option for most investors at the moment. AbbVie's recent acquisition of Apogee Therapeutics and its promising pipeline of internal treatments provide a foundation for years of growth. Additionally, AbbVie has set an aggressive target for net income growth and sales expansion. Bristol Myers Squibb, while making progress, still faces challenges in convincing investors of its long-term growth potential. As such, investors seeking a turnaround play may consider Bristol Myers Squibb, but for most investors, AbbVie is the better choice at this time.",
  "summary": "AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}